The Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes- A Literature Review

References

• Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21:6275.
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas. Diabetes facts & figures; 2021.
   Google Scholar
• Pulgaron ER, Delamater AM. Obesity and type 2 diabetes in children: epidemiology and treatment. Curr Diab Rep. 2014;14(8):508. doi:10.1007/s11892-014-0508-y
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. doi:10.1186/s12933-018-0728-6
   PubMed Web of Science ®Google Scholar
• Samar Hafida M. Type 2 Diabetes: Which Medication is Best for Me? Harvard health publishing; 2020.
   Google Scholar
• American Diabetes Association. Summary of revisions: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S4–s6. doi:10.2337/dc20-Srev
   PubMedGoogle Scholar
• Peracha J, Nath J, Ready A, et al. Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients. Transpl Int. 2016;29(6):727–739. doi:10.1111/tri.12782
   PubMed Web of Science ®Google Scholar
• Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ. 2015;18(1):45–55. doi:10.3111/13696998.2014.971158
   PubMed Web of Science ®Google Scholar
• Kokil GR, Veedu RN, Ramm GA, et al. Type 2 diabetes mellitus: limitations of conventional therapies and intervention with nucleic acid-based therapeutics. Chem Rev. 2015;115(11):4719–4743. doi:10.1021/cr5002832
   PubMed Web of Science ®Google Scholar
• Solis MA, Moreno Velásquez I, Correa R, et al. Stem cells as a potential therapy for diabetes mellitus: a call-to-action in Latin America. Diabetol Metab Syndr. 2019;11(1):20. doi:10.1186/s13098-019-0415-0
   PubMedGoogle Scholar
• Unnisa A, Dua K, Kamal MA. Mechanism of mesenchymal stem cells as a multitarget disease-modifying therapy for Parkinson’s disease. Curr Neuropharmacol. 2022;20. doi:10.2174/1570159X20666220327212414
   Google Scholar
• Visweswaran M, Hendrawan K, Massey JC, et al. Sustained immunotolerance in multiple sclerosis after stem cell transplant. Ann Clin Transl Neurol. 2022;9(2):206–220. doi:10.1002/acn3.51510
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, Phase 3 trial. Lancet Oncol. 2021;22(10):1378–1390. doi:10.1016/S1470-2045(21)00428-9
   PubMed Web of Science ®Google Scholar
• Bani Hamad FR, Rahat N, Shankar K, et al. Efficacy of stem cell application in diabetes mellitus: promising future therapy for diabetes and its complications. Cureus. 2021;13(2):e13563. doi:10.7759/cureus.13563
   PubMed Web of Science ®Google Scholar
• Moreira A, Kahlenberg S, Hornsby P. Therapeutic potential of mesenchymal stem cells for diabetes. J Mol Endocrinol. 2017;59(3):R109–r120. doi:10.1530/JME-17-0117
   PubMed Web of Science ®Google Scholar
• Schu S, Nosov M, O’Flynn L, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med. 2012;16(9):2094–2103. doi:10.1111/j.1582-4934.2011.01509.x
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Hoang DM, Nguyen KT, et al. Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. Stem Cells Transl Med. 2021;10(9):1266–1278. doi:10.1002/sctm.20-0506
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao S, Mao H, et al. Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus. Chin Med J. 2011;124(22):3622–3628.
   PubMed Web of Science ®Google Scholar
• Hu J, Wang Y, Gong H, et al. Long term effect and safety of Wharton’s jelly-derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med. 2016;12(3):1857–1866. doi:10.3892/etm.2016.3544
   PubMed Web of Science ®Google Scholar
• Chen P, Huang Q, Xu XJ, et al. 利拉鲁肽联合人脐带间充质干细胞治疗对2型糖尿病患者糖代谢及胰岛β细胞功能的作用 [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus]. Zhonghua Nei Ke Za Zhi. 2016;55(5):349–354. Chinese. doi:10.3760/cma.j.issn.0578-1426.2016.05.004
   PubMedGoogle Scholar
• Jiang R, Han Z, Zhuo G, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5(1):94–100. doi:10.1007/s11684-011-0116-z
   PubMedGoogle Scholar
• Bhansali S, Dutta P, Kumar V, et al. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized placebo-controlled comparative study. Stem Cells Dev. 2017;26(7):471–481. doi:10.1089/scd.2016.0275
   PubMed Web of Science ®Google Scholar
• Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017;8(3):475–487. doi:10.1007/s13300-017-0265-4
   PubMed Web of Science ®Google Scholar
• Sherwani SI, Khan HA, Ekhzaimy A, et al. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:BMI.S38440. doi:10.4137/BMI.S38440
   PubMedGoogle Scholar
• Lee M-Y, Huang J-C, Chen S-C, et al. Association of HbA1C variability and renal progression in patients with type 2 diabetes with chronic kidney disease stages 3–4. Int J Mol Sci. 2018;19(12):4116. doi:10.3390/ijms19124116
   PubMed Web of Science ®Google Scholar
• Berglund AK, Fortier LA, Antczak DF, et al. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res Ther. 2017;8(1):288. doi:10.1186/s13287-017-0742-8
   PubMed Web of Science ®Google Scholar
• Moassesfar S, Masharani U, Frassetto LA, et al. A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am J Transplant. 2016;16(2):518–526. doi:10.1111/ajt.13536
   PubMed Web of Science ®Google Scholar